ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2119

Association of the Variant Form of rs17408553 at Human Leukocyte Antigen-C Supports Evidence That Hypo-Responsive Natural Killer Cells Adversely Influence the Course of Nephritis

Robert M. Clancy1, H. Michael Belmont1, Peter M. Izmirly2, Nicole Bornkamp3, Sarah Miller4, Matthew Poulin4, Liying Yan4, Jill P. Buyon1 and Ellen M. Ginzler5, 1NYU School of Medicine, New York, NY, 2Rheumatology, NYU School of Medicine, New York, NY, 3Medicine, NYU School of Medicine, New York, NY, 4EpigenDx, Hopkinton, MA, 5Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: DNA, Genetic Biomarkers, SLE and major histocompatibility complex (MHC)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In subjects with lupus nephritis (LN), tissue injury due to local immune activation involving persistently activated macrophages in the renal parenchyma is limited by non-classical natural killer (NK) cells. This protective pathway, based on a genetic effect related to the NK ligand Human Leukocyte Antigen (HLA)-C, was recently shown to limit activation of macrophages and dendritic cells by immune stimuli in vitro. A risk phenotype of HLA Class I, termed the Lys variant, or the C2 epitope or Asn80Lys, rs17408553, leads to a hypo-responsive NK cell which is secondary to high affinity of ligand by variant and an inhibitory NK receptor. The clinical impact of these pathways is understudied; the aim of this study, therefore, is to evaluate associations of clinical outcomes among subjects carrying the risk genotype in two cohorts of SLE patients.

Methods: Patients were included if there was confirmation of a diagnosis of SLE as per the ACR and access to chart review along with DNA for genotyping. There were 2 patient subsets: 96 lupus nephritis (LN) patients who were selected from SLE cohorts from the ALMS trial (27 LN) and the NYU Specimen and Matched Phenotype Linked Evaluation (SAMPLE, 69 LN), and the second subgroup was SLE absent lupus nephritis (NN) (SAMPLE, 33 NN). LN were adjudicated for response to induction therapy and DNA specimens were genotyped at rs17408553 using a Pyrosequencing assay (ADS9525-RS) and the result is reported as minor allelic frequency (MAF). While pyrosequencing is performed in the usual way, it is noteworthy that the PCR fragment of HLA-C containing the rs17408553 SNP was designed to exclude the very similar HLA-B gene by the specificity of the PCR primers, which can be monitored by one nucleic acid that differs between HLA-C and HLA-B within the PCR amplicon.

Results: Demographic characteristics of LN and NN were matched for age, gender, and ethnicity. LN biopsies encompassed all ISN/RPS classes, the majority of which were proliferative forms. For LN, 35% had hypertension, 47% had nephrotic range proteinuria, and a majority were given an induction therapy consisting of steroids plus mycophenolate mofetil. At six months, 14 LN patients were non-responders, 8 were partial responders and 74 were complete responders. For MAF at rs17408553, the C2 allele was enriched in LN patients compared to controls (0.45 vs 0.37, SLE (LN+NN) vs control; OR 1.40, P=0.01). However, for a comparison of LN and NN, the frequencies of C2 were found to be similar (0.45 vs 0.45, LN vs NN, P=1). While LN spot prot/cr ratios were similar in C1/C1 and C2/N groups at the end of induction (3.86 ± 3.02 vs 4.64 ± 3.30, P=0.52), there was an association of an increase in variant allele and LN patients with no response at induction (0.73 vs 0.41, LN non-response vs LN response, P=0.0149). The association of variant at HLA-C and subjects with non-response was observed in both LN cohorts (ALMS trial and SAMPLE).

Conclusion: Using two distinct and well-characterized cohorts, there was an association of variant at HLA-C and subjects with non-response to induction therapy. These data support the speculation that hypo-responsive NK cells adversely influence the course of nephritis.


Disclosure: R. M. Clancy, None; H. M. Belmont, Exagen, 2; P. M. Izmirly, None; N. Bornkamp, None; S. Miller, EpigenDx, 3; M. Poulin, EpigenDx, 3; L. Yan, EpigenDx, 3; J. P. Buyon, Exagen, 2; E. M. Ginzler, None.

To cite this abstract in AMA style:

Clancy RM, Belmont HM, Izmirly PM, Bornkamp N, Miller S, Poulin M, Yan L, Buyon JP, Ginzler EM. Association of the Variant Form of rs17408553 at Human Leukocyte Antigen-C Supports Evidence That Hypo-Responsive Natural Killer Cells Adversely Influence the Course of Nephritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/association-of-the-variant-form-of-rs17408553-at-human-leukocyte-antigen-c-supports-evidence-that-hypo-responsive-natural-killer-cells-adversely-influence-the-course-of-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-the-variant-form-of-rs17408553-at-human-leukocyte-antigen-c-supports-evidence-that-hypo-responsive-natural-killer-cells-adversely-influence-the-course-of-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology